Overall rank by patents
#40,696
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Halia Therapeutics, Inc.
USPTO PatentsView assignee record - 6 granted patents across 2 technology areas, active 2021–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
6
Total patents granted
2
CPC technology areas
24.0
Avg claims per patent
-
5-year filing velocity
The verdict
Halia holds 6 US patents across 2 technology areas, rank #40,696 of 50,000 tracked assignees.
- #40,696
- of 50,000 US assignees by volume
- Top 22%
- by Innovation Score (46.1/100)
- 24.0
- avg claims per patent
Portfolio overview
Halia Therapeutics, Inc. has been granted 6 US utility patents between 2021 and 2025, placing Halia Therapeutics, Inc. at rank #40,696 across all assignees tracked by PlainPatent. This portfolio spans 2 distinct Cooperative Patent Classification (CPC) subclasses, averaging 24.0 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Halia Therapeutics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Halia sits between Hyperkinetics Corporation (6 patents, rank #40,692) and Hamilton Caster & Manufacturing Company (6 patents, rank #40,700) - the closest US assignees by grant volume. The composite Innovation Score of 46.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2021 through 2025, with 6 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Halia Therapeutics, Inc.'s 24.0 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while specialization in 2 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Halia Therapeutics, Inc. against peers pursuing similar technology classes.
Who files at Halia's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Hyperkinetics
HYPERKINETICS CORPORATION
6 patents
- Hytrans Beheer B V
HYTRANS BEHEER B.V.
6 patents
- Hackproof
Hackproof Technologies Inc.
6 patents
- Hako
Hako GmbH
6 patents
- Hall Fabrication
Hall Fabrication, Inc.
6 patents
- Hamamatsu Univers…
Hamamatsu University School of Medicine
6 patents
- Hamfop
Hamfop Technologies LLC
6 patents
- Hamilton Caster &…
Hamilton Caster & Manufacturing Company
6 patents
- Halia Therapeutics ◀
Halia Therapeutics, Inc.
6 patents
What this shows Halia holds 6 patents at rank #40,696, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Halia
By rank, the assignees closest to #40,696 in granted patent volume.
- Hyperkinetics Corporation #40,692 · 6 patents
- Hytrans Beheer B.v. #40,693 · 6 patents
- Hackproof Technologies Inc. #40,694 · 6 patents
- Hako Gmbh #40,695 · 6 patents
- Hall Fabrication, Inc. #40,697 · 6 patents
- Hamamatsu University School Of Medicine #40,698 · 6 patents
- Hamfop Technologies Llc #40,699 · 6 patents
- Hamilton Caster & Manufacturing Company #40,700 · 6 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Halia's primary technology class.
- The Regents Of The University Of California 1,387 in class
- Novartis Ag 1,071 in class
- Merck Sharp & Dohme Llc 889 in class
- Bristol-myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board Of Regents Of The University Of Texas System 744 in class
- Hoffmann-la Roche Inc. 722 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721 in class
Halia's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
46 Top 22% higher than 78% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2021 | 1 | 16.7% |
| 2023 | 2 | 33.3% |
| 2024 | 2 | 33.3% |
| 2025 | 1 | 16.7% |
Which technologies does Halia Therapeutics, Inc. patent most?
Top 2 of 2 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Complex
Frequently Asked Questions
How many patents does Halia Therapeutics, Inc. hold?
Halia Therapeutics, Inc. holds 6 US granted patents filed between 2021 and 2025, spanning 2 technology areas.
What is Halia Therapeutics, Inc.'s Innovation Score?
Halia Therapeutics, Inc. has an Innovation Score of 46.1 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Halia Therapeutics, Inc. focus on?
Halia Therapeutics, Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 6 patents. The company has filed patents in 2 CPC subclasses total.
Is Halia Therapeutics, Inc.'s patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Halia Therapeutics, Inc..
What does claim depth mean for Halia Therapeutics, Inc.'s patents?
Halia Therapeutics, Inc.'s patents average 24.0 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Halia Therapeutics, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Halia's 6 grants land it in the top 22% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Halia ranks #40,696 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.